Environmental Health Science and Research Bureau, Environmental and Radiation Health Sciences Directorate, Healthy Environment and Consumer Safety Branch, Health Canada, Ottawa, ON, Canada.
Bureau of Chemical Safety, Food Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada.
Arch Toxicol. 2022 Jul;96(7):2067-2085. doi: 10.1007/s00204-022-03286-2. Epub 2022 Apr 21.
Risk assessments are increasingly reliant on information from in vitro assays. The in vitro micronucleus test (MNvit) is a genotoxicity test that detects chromosomal abnormalities, including chromosome breakage (clastogenicity) and/or whole chromosome loss (aneugenicity). In this study, MNvit datasets for 292 chemicals, generated by the US EPA's ToxCast program, were evaluated using a decision tree-based pipeline for hazard identification. Chemicals were tested with 19 concentrations (n = 1) up to 200 µM, in the presence and absence of Aroclor 1254-induced rat liver S9. To identify clastogenic chemicals, %MN values at each concentration were compared to a distribution of batch-specific solvent controls; this was followed by cytotoxicity assessment and benchmark concentration (BMC) analyses. The approach classified 157 substances as positives, 25 as negatives, and 110 as inconclusive. Using the approach described in Bryce et al. (Environ Mol Mutagen 52:280-286, 2011), we identified 15 (5%) aneugens. IVIVE (in vitro to in vivo extrapolation) was employed to convert BMCs into administered equivalent doses (AEDs). Where possible, AEDs were compared to points of departure (PODs) for traditional genotoxicity endpoints; AEDs were generally lower than PODs based on in vivo endpoints. To facilitate interpretation of in vitro MN assay concentration-response data for risk assessment, exposure estimates were utilized to calculate bioactivity exposure ratio (BER) values. BERs for 50 clastogens and two aneugens had AEDs that approached exposure estimates (i.e., BER < 100); these chemicals might be considered priorities for additional testing. This work provides a framework for the use of high-throughput in vitro genotoxicity testing for priority setting and chemical risk assessment.
风险评估越来越依赖于体外检测数据。体外微核试验(MNvit)是一种检测染色体异常的遗传毒性检测方法,包括染色体断裂(致裂性)和/或整条染色体缺失(非整倍体性)。本研究使用基于决策树的分析管道,对美国环保署 ToxCast 计划生成的 292 种化合物的 MNvit 数据集进行了评估,以识别危害。这些化合物在 Aroclor 1254 诱导的大鼠肝 S9 存在或不存在的情况下,用 19 个浓度(n=1)进行测试,最高可达 200 μM。为了鉴定致裂性化合物,在每个浓度下的 MN 值与批次特异性溶剂对照的分布进行比较;随后进行细胞毒性评估和基准浓度(BMC)分析。该方法将 157 种物质归类为阳性,25 种为阴性,110 种为不确定。使用 Bryce 等人描述的方法(Environ Mol Mutagen 52:280-286, 2011),我们确定了 15 种(5%)非整倍体形成剂。体外至体内外推法(IVIVE)用于将 BMC 转换为给药等效剂量(AED)。在可能的情况下,将 AED 与传统遗传毒性终点的起点(POD)进行比较;基于体内终点,AED 通常低于 POD。为了促进体外 MN 测定浓度-反应数据在风险评估中的解释,利用暴露估计值来计算生物活性暴露比(BER)值。50 种致裂剂和两种非整倍体形成剂的 BER 值的 AED 接近暴露估计值(即,BER<100);这些化合物可能被认为是进一步测试的优先事项。这项工作为使用高通量体外遗传毒性测试进行优先级设置和化学风险评估提供了一个框架。